NextCure

NXTC46

Penny Stock

$1.39arrow_drop_down0.71%-$0.01

Penny Stock

NXTC46

$1.39

arrow_drop_down0.71%-$0.01

Penny Stock

Performance History

Key Stats
Open	$1.39
Prev. Close	$1.40
EPS	-2.19
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-
Market Cap	$39.16M
PE Ratio	-

	LOW	HIGH
Day Range	1.36	1.45
52 Week Range	0.98	2.57

Ratios

Revenue	-



EBITDA Margin %	-

EPS	-2.19

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About NextCure (NXTC)

NextCure Inc. (NXTC) is a biopharmaceutical company focused on discovering and developing novel, highly selective immunomedicine therapies to improve outcomes for cancer patients. The company's proprietary FIND-IO platform identifies immunomodulatory targets with the goal of enabling a new generation of therapies that harness the immune system to fight cancer. NextCure's approach is based on the recognition that the tumor microenvironment plays a crucial role in shaping the immune response to cancer and that targeting specific immune cell subsets within the tumor microenvironment can lead to improved clinical outcomes.

NextCure's lead product candidate, NC318, is currently in clinical development for the treatment of advanced or metastatic solid tumors. NC318 is an immune checkpoint protein that NextCure believes may have broad therapeutic potential across a range of cancers. The company is currently conducting multiple phase 1/2 clinical trials to evaluate the safety, tolerability, and efficacy of NC318 both as a monotherapy and in combination with other cancer therapies.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Mr. Michael S. Richman MSBA
Headquarters: Beltsville
Employees: 99
Exchange: NASDAQ

Keep an eye on NextCure

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is NextCure 's (NXTC) price per share?

The current price per share for NextCure (NXTC) is $1.39. The stock has seen a price change of -$0.01 recently, indicating a -0.71% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for NextCure (NXTC)?

For NextCure (NXTC), the 52-week high is $2.57, which is 84.89% from the current price. The 52-week low is $0.98, the current price is 41.84% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is NextCure (NXTC) a growth stock?

NextCure (NXTC) has shown an average price growth of 0.41% over the past three years. It has received a score of 11 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying NextCure as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is NextCure (NXTC) stock price performance year to date (YTD)?

As of the latest data, NextCure (NXTC) has a year-to-date price change of 20.87%. Over the past month, the stock has experienced a price change of -13.66%. Over the last three months, the change has been -17.26%. Over the past six months, the figure is -30.15%. Looking at a longer horizon, the five-year price change stands at -96.36%.

help

Is NextCure (NXTC) a profitable company?

NextCure (NXTC) has a net income of -$62.72M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 0% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$67.64M. Furthermore, the EBITDA is -$60.4M.

help

What is the market capitalization of NextCure (NXTC)?

NextCure (NXTC) has a market capitalization of $39.17M. The average daily trading volume is 54.55K, indicating the stock's liquidity and investor engagement.